New shot aims to slash hidden heart risk in 203 patients
NCT ID NCT07185776
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 31 times
Summary
This study tests an experimental drug called HRS-5632 in 203 adults with high levels of lipoprotein(a), a fatty substance that raises the risk of heart attacks and strokes. Participants receive either the drug or a placebo to see if it safely lowers their Lp(a) levels. The goal is to control this long-term risk factor, not to cure the underlying condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIPOPROTEIN DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, 710061, China
-
The Second Affiliated Hospital of AFMU
Xi’an, Shanxi, 710038, China
Conditions
Explore the condition pages connected to this study.